Centaurus Financial Inc. Has $416,000 Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Centaurus Financial Inc. increased its position in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 5.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,804 shares of the company’s stock after acquiring an additional 142 shares during the period. Centaurus Financial Inc.’s holdings in Zoetis were worth $416,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ZTS. Psagot Value Holdings Ltd. Israel bought a new position in Zoetis in the 3rd quarter valued at approximately $25,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its stake in Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the last quarter. Worth Asset Management LLC bought a new position in Zoetis in the 1st quarter valued at approximately $26,000. McClarren Financial Advisors Inc. bought a new position in Zoetis in the 3rd quarter valued at approximately $31,000. Finally, Vienna Asset Management LLC bought a new position in Zoetis in the 3rd quarter valued at approximately $33,000. Institutional investors and hedge funds own 90.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. StockNews.com assumed coverage on shares of Zoetis in a research note on Thursday. They issued a “buy” rating for the company. Barclays increased their price objective on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Tuesday, February 21st. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $223.83.

Zoetis Price Performance

ZTS stock opened at $164.47 on Friday. The company has a fifty day moving average price of $165.25 and a 200-day moving average price of $155.25. The company has a market capitalization of $76.21 billion, a P/E ratio of 36.55, a PEG ratio of 2.53 and a beta of 0.76. Zoetis Inc. has a 52-week low of $124.15 and a 52-week high of $201.32. The company has a debt-to-equity ratio of 1.49, a quick ratio of 1.63 and a current ratio of 2.37.

Zoetis (NYSE:ZTS – Get Rating) last announced its earnings results on Tuesday, February 14th. The company reported $1.15 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.15. Zoetis had a net margin of 26.16% and a return on equity of 50.20%. The business had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter last year, the firm earned $1.00 earnings per share. Zoetis’s quarterly revenue was up 3.7% on a year-over-year basis. As a group, equities analysts expect that Zoetis Inc. will post 5.39 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Friday, April 21st will be paid a dividend of $0.375 per share. This represents a $1.50 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, April 20th. Zoetis’s dividend payout ratio is presently 33.33%.

About Zoetis

(Get Rating)

Zoetis, Inc engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments. The United States segment is involved in U.S.